Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Natoli

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Archives of Pathology & Laboratory Medicine|March 14, 1998
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10(6) cells/LN Tinari, C Natoli, N D'Ostilio, et al.
Digestive Diseases and Sciences|May 11, 1999
Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferonP L Almasio, V Di Marco, C Bonura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancerC Natoli, E Cianchetti, N Tinari, et al.
Molecular Biology and Evolution|November 27, 2019
Visual Opsin Diversity in Sharks and RaysNathan S Hart, Trevor D Lamb, Hardip R Patel, et al.
British Journal of Cancer|August 5, 2004
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding studyC Ficorella, M F Morelli, E Ricevuto, et al.
Journal of Hematology & Oncology|October 31, 2019
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectivesE Krasniqi, G Barchiesi, L Pizzuti, et al.
Journal of Oncology|April 23, 2020
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation"D Brocco, P Lanuti, P Simeone, et al.
Journal of Oncology|December 13, 2019
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome EvaluationD Brocco, P Lanuti, P Simeone, et al.
Breast (Edinburgh, Scotland)|August 1, 2016
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experienceL Moscetti, P Vici, T Gamucci, et al.
Biomarker Research|July 14, 2021
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics studyE Krasniqi, A Sacconi, D Marinelli, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Archives of Pathology & Laboratory Medicine|March 14, 1998
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10(6) cells/LN Tinari, C Natoli, N D'Ostilio, et al.
Digestive Diseases and Sciences|May 11, 1999
Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferonP L Almasio, V Di Marco, C Bonura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancerC Natoli, E Cianchetti, N Tinari, et al.
Molecular Biology and Evolution|November 27, 2019
Visual Opsin Diversity in Sharks and RaysNathan S Hart, Trevor D Lamb, Hardip R Patel, et al.
British Journal of Cancer|August 5, 2004
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding studyC Ficorella, M F Morelli, E Ricevuto, et al.
Journal of Hematology & Oncology|October 31, 2019
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectivesE Krasniqi, G Barchiesi, L Pizzuti, et al.
Journal of Oncology|April 23, 2020
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation"D Brocco, P Lanuti, P Simeone, et al.
Journal of Oncology|December 13, 2019
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome EvaluationD Brocco, P Lanuti, P Simeone, et al.
Breast (Edinburgh, Scotland)|August 1, 2016
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experienceL Moscetti, P Vici, T Gamucci, et al.
Biomarker Research|July 14, 2021
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics studyE Krasniqi, A Sacconi, D Marinelli, et al.
Pageof 10